Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

OBJECTIVES: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. DESIGN: This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Infect Dis
Main Authors: Generali, Daniele, Bosio, Giancarlo, Malberti, Fabio, Cuzzoli, Antonio, Testa, Sophie, Romanini, Laura, Fioravanti, Antonio, Morandini, Alessandro, Pianta, Luca, Giannotti, Guglielmo, Viola, Erika Maria, Giorgi-Pierfranceschi, Matteo, Foramitti, Marina, Tira, Rosa Angela, Zangrandi, Ilaria, Chiodelli, Giulia, Machiavelli, Andrea, Cappelletti, Maria Rosa, Giossi, Alessia, De Giuli, Valeria, Costanzi, Chiara, Campana, Chiara, Bernocchi, Ottavia, Sirico, Marianna, Zoncada, Alessia, Molteni, Alfredo, Venturini, Sergio, Giudici, Fabiola, Scaltriti, Maurizio, Pan, Angelo
Formato: Artigo
Idioma:Inglês
Publicado em: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771302/
https://ncbi.nlm.nih.gov/pubmed/33385581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2020.12.073
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados